Current Pharmaceutical Biotechnology - Volume 17, Issue 9, 2016

During drug development, large libraries of new chemical entities (NCEs) are generated and undergo in vitro screens of metabolism and cytotoxicity. These screens are heavily relied upon to select lead compounds with the highest chance of success in pre-clinical studies and clinical trials, but suffer from limited in vivo predictive power despite using human liver-derived components. There is a need for new assays tha Read More

Therapeutic drugs administered systematically are evenly distributed to the whole body through blood circulation and have to cross many biological barriers before reaching the pathological site. Conventional drug delivery may make drugs inactive or reduce their potency as they may be hydrolyzed or degraded enzymatically and are rapidly excreted through the urinary system resulting in suboptimal concentration of dru Read More

Therapeutic monoclonal antibodies (mAbs) have made a tremendous impact in treating patients with various diseases. MAbs are designed to specifically target a cell and illicit a response from the immune system to destroy the cell. As originator mAb drug patents are coming to an end, generic pharmaceutical companies are poised to replicate and produce so-called biosimilar drugs. MAbs are significantly more complica Read More

Cancer, as the most serious threat to human health, poses millions of deaths in the world each year. In vitro cancer cell and biomarker detection is of great importance for early cancer diagnosis and therapy, which needs highly sensitive, selective and quantitative diagnosis platforms. Threedimensional paper-based electrochemical devices (3D-PEDs) have attracted considerable interest in biomedical fields in recent ye Read More

The research of circulating tumor cells (CTCs) has drawn much attention in recent years. It is because of the potential values of CTCs in early diagnosis of cancer, management of clinical treatment, exploration of metastatic mechanism, and development of personalized medicine. However, isolating CTCs has been technically challenging due to their rare numbers in blood. Recently, a variety of microfluidic devices h Read More

Drug discovery is a long and expensive process, which usually takes 12-15 years and could cost up to ~$1 billion. Conventional drug discovery process starts with high throughput screening and selection of drug candidates that bind to specific target associated with a disease condition. However, this process does not consider whether the chosen candidate is optimal not only for binding but also for ease of administration Read More

This work aimed to characterize and evaluate the antihypertensive effect of the (-)-β-pinene/β-cyclodextrin (βP/β-CD) complex. The complex was prepared through physical mixture and slurry complexation methods and was analyzed through differential scanning calorimetry, thermogravimetry/derivative thermogravimetry, fourier transform infrared spectroscopy, diffraction X-ray, docking and scanning electr Read More